Cyclic boronates as versatile scaffolds for KPC-2 β-lactamase inhibition. Issue 4 (23rd January 2020)

• Record Type: Journal Article
• Authors: Tooke, Catherine L.; Hinchliffe, Philip; Krajnc, Alen; Mulholland, Adrian J.; Brem, Jürgen; Schofield, Christopher J.; Spencer, James
• Is Part Of: RSC medicinal chemistry. Volume 11:Issue 4(2020)
• Page Start: 491
• Page End: 496
• Publication Date: 2020-01-23
• Subjects: Pharmaceutical chemistry -- Periodicals; 615.19005
• DOI: 10.1039/c9md00557a
• Languages: English
• ISSNs: 2632-8682

Abstract

Abstract : Mono- (vaborbactam) and bi-cyclic (taniborbactam) boronate inhibitors bind KPC-2 similarly, but the latter is essentially irreversible. Abstract : Klebsiella pneumoniae carbapenemase-2 (KPC-2) is a serine-β-lactamase (SBL) capable of hydrolysing almost all β-lactam antibiotics. We compare KPC-2 inhibition by vaborbactam, a clinically-approved monocyclic boronate, and VNRX-5133 (taniborbactam), a bicyclic boronate in late-stage clinical development. Vaborbactam inhibition is slowly reversible, whereas taniborbactam has an off-rate indicating essentially irreversible complex formation and a 15-fold higher on-rate, although both potentiate β-lactam activity against KPC-2-expressing K. pneumoniae . High resolution X-ray crystal structures reveal closely related binding modes for both inhibitors to KPC-2, with differences apparent only in positioning of the endocyclic boronate ester oxygen. The results indicate the bicyclic boronate scaffold as both an efficient, long-lasting, KPC-2 inhibitor and capable of supporting further iterations that may improve potency against specific enzyme targets and pre-empt the emergence of inhibitor resistant KPC-2 variants.